Search
Travere Therapeutics Inc
TVTXAdd to Watchlist
65.670USD
-1.850-2.74%
Close 08-28 16:00（ET）
5.97BMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-28The current earnings forecast score of Travere Therapeutics Inc is 8.67, ranking 76 out of 377 in the Biotechnology & Medical Research industry. The average price target is 41.00, with a high of 49.00 and a low of 31.00.
Analyst Rating
Based on
15
analysts
Buy
Current Rating
72.154
Target Price
+7.50%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Travere Therapeutics Inc
TVTX
15
argenx SE
ARGX
28
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
26
Kymera Therapeutics Inc
KYMR
24
IQVIA Holdings Inc
IQV
24
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Travere Therapeutics Inc's expected revenue for the next quarter?
Travere Therapeutics Inc's expected revenue is 194.60M.
What is Travere Therapeutics Inc's price target?
Analysts forecast that Travere Therapeutics Inc's price target is USD 41.00, with the highest forecast at USD 49.00 and the lowest forecast at USD 31.00.
How have Travere Therapeutics IncTVTX's recent earnings per share performed?
The market expectation was USD -0.37, while Travere Therapeutics IncTVTX's earnings per share (EPS) for the previous quarter was USD -0.40. EPS for the next quarter is expected at USD -0.01.
What is the analyst rating for Travere Therapeutics Inc?
Based on the ratings of Travere Therapeutics Inc's stock from 15 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.